Molsidomine

Catalog No.S4664 Batch:S466403

Technical Data

Formula	C₉H₁₄N₄O₄
Molecular Weight	242.23	CAS No.	25717-80-0
Solubility (25°C)*	In vitro	DMSO	49 mg/mL (202.28 mM)
		Water	24 mg/mL (99.07 mM)
		Ethanol	24 mg/mL (99.07 mM)
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description	Molsidomine (SIN-10, Corvaton, Morsydomine) is an orally active, long acting vasodilating drug. Molsidomine is metabolized in the liver to the active metabolite linsidomine. Linsidomine is an unstable compound that releases nitric oxide (NO) upon decay as the actual vasodilating compound.
In vivo	Molsidomine (50, 100, 250 μg/kg) reduces coronary flow while the coronary resistance remains unaffected by molsidomine. Molsidomine decreases myocardial oxygen consumption. Heart rate and contractility remains unchanged by molsidomine. Stroke volume and cardiac output fall after molsidomine. The fall in blood pressure after molsidomine follows the reduction in cardiac output as sequel of lowered preload and venous return to the heart^[1].

Description

Molsidomine (SIN-10, Corvaton, Morsydomine) is an orally active, long acting vasodilating drug. Molsidomine is metabolized in the liver to the active metabolite linsidomine. Linsidomine is an unstable compound that releases nitric oxide (NO) upon decay as the actual vasodilating compound.

In vivo

Molsidomine (50, 100, 250 μg/kg) reduces coronary flow while the coronary resistance remains unaffected by molsidomine. Molsidomine decreases myocardial oxygen consumption. Heart rate and contractility remains unchanged by molsidomine. Stroke volume and cardiac output fall after molsidomine. The fall in blood pressure after molsidomine follows the reduction in cardiac output as sequel of lowered preload and venous return to the heart^[1].

Protocol (from reference)

Animal Study:^{^[1]}	Animal Models Adult mongrel dogs Dosages 50, 100, 250 μg/kg Administration i.v.

References

[1] Volker B. Fiedler, et al. Naunyn-Schmiedeberg's Archives of Pharmacology. 1981, 317(1):71-77.

Selleck's Molsidomine has been cited by 1 publication

C-Type Lectin Receptor CD23 Is Required for Host Defense against Candida albicans and Aspergillus fumigatus Infection. [ J Immunol, 2018, 201(8):2427-2440]	PubMed: 30185519

C-Type Lectin Receptor CD23 Is Required for Host Defense against Candida albicans and Aspergillus fumigatus Infection. [ J Immunol, 2018, 201(8):2427-2440]

PubMed: 30185519

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.